Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 2, 2015, Pages 607-616

  Llauradó, Gemma ^a,f   Sevastianova, Ksenia ^a,b   Sädevirta, Sanja ^b   Hakkarainen, Antti ^c   Lundbom, Nina ^c   Orho Melander, Marju ^d   Groop, Per Henrik ^e   Forsblom, Carol ^e   Yki Järvinen, Hannele ^a,b  

^a MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d LUND UNIVERSITY   (Sweden)

^e FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^f UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCOSE; INSULIN; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FAT CONTENT; FAT FREE MASS; FATTY ACID BLOOD LEVEL; FATTY LIVER; FEMALE; GENE; GENOTYPE; GLUCONEOGENESIS; HUMAN; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; LIPOLYSIS; LIVER FAT CONTENT; LIVER FUNCTION TEST; MALE; OBESITY; PNPLA3 GENE; PRIORITY JOURNAL; ADIPOSE TISSUE; COMPLICATION; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADIPOSE TISSUE; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MALE; MIDDLE AGED; OVERWEIGHT;

EID: 84922576094     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3050     Document Type: Article

References (44)

1. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States From 1988 to 2008. Clin GastroenterolHepatol. 2011; 9: 524-530 e521; quiz e560.
2. Kotronen A, Westerbacka J, Bergholm R, Pietiläinen KH, Yki-Järvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab. 2007; 92: 3490-3497.
3. Ferrannini E, Wahren J, Faber OK, Felig P, Binder C, DeFronzo RA. Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. Am J Physiol. 1983; 244: E517-E527.
4. Hother-Nielsen O, Schmitz O, Bak J, Beck-Nielsen H. Enhanced hepatic insulin sensitivity, but peripheral insulin resistance in patients with type 1 (insulin-dependent) diabetes. Diabetologia. 1987; 30: 834-840.
5. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005; 115: 1343-1351.
6. Kotronen A, Juurinen L, Tiikkainen M, Vehkavaara S, Yki-Järvinen H. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology. 2008; 135: 122-130.
7. Magkos F, Su X, Bradley D, Fabbrini E, et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistancein obese subjects. Gastroenterology. 2012; 142: 1444-1446.e2.
8. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002; 87: 3023-3028.
9. Perseghin G, Lattuada G, De Cobelli F, et al. Reduced intrahepatic fat content is associated with increased whole-body lipid oxidation in patients with type 1 diabetes. Diabetologia. 2005; 48: 2615-2621.
10. Ryysy L, Häkkinen AM, Goto T, et al. Hepatic fat content and insulin action onfree fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes. 2000; 49: 749-758.
11. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008; 40: 1461-1465.
12. Thorn LM, Forsblom C, Fagerudd J, et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care. 2005; 28: 2019-2024.
13. Kotronen A, Vehkavaara S, Seppälä-Lindroos A, Bergholm R, Yki-Järvinen H. Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab. 2007; 293: E1709-E1715.
14. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979; 237: E214-E223.
15. Yki-Järvinen H, Young AA, Lamkin C, Foley JE. Kinetics of glucose disposal in whole body and across the forearm in man. J Clin Invest. 1987; 79: 1713-1719.
16. Juurinen L, Tiikkainen M, Häkkinen AM, Hakkarainen A, Yki-Järvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab. 2007; 292: E829-E835.
17. Sevastianova K, Kotronen A, Gastaldelli A, et al. Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am J Clin Nutr. 2011; 94: 104-111.
18. Cowan JS, Hetenyi G Jr. Glucoregulatory responses in normal and diabetic dogs recorded by a new tracer method. Metabolism. 1971; 20: 360-372.
19. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci. 1959; 82: 420-430.
20. Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of nonalcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009; 137: 865-872.
21. Yki-Järvinen H, Koivisto VA. Insulin sensitivity in newly diagnosed type 1 diabetics after ketoacidosis and after three months of insulin therapy. J Clin Endocrinol Metab. 1984; 59: 371-378.
22. Del Prato S, Matsuda M, Simonson DC, et al. Studies on the mass action effect of glucose in NIDDM and IDDM: evidence for glucose resistance. Diabetologia. 1997; 40: 687-697.
23. Yki-Järvinen H, Koivisto VA. Continuous subcutaneous insulin infusion therapy decreases insulin resistance in type 1 diabetes. J Clin Endocrinol Metab. 1984; 58: 659-666.
24. Groop LC, Bonadonna RC, DelPrato S, et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest. 1989; 84: 205-213.
25. Yki-Järvinen H, Mäkimattila S, Utriainen T, Rutanen EM. Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein1invivo. J Clin Endocrinol Metab. 1995; 80: 3227-3232.
26. Mäkimattila S, Virkamäki A, Groop PH, et al. Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. Circulation. 1996; 94: 1276-1282.
27. Yki-Järvinen H, Koivisto VA. Natural course of insulin resistance in type I diabetes. N Engl J Med. 1986; 315: 224-230.
28. Targher G, Bertolini L, Padovani R, et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol. 2010; 53: 713-718.
29. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell. 2000; 6: 77-86.
30. Bergman BC, Howard D, Schauer IE, et al. The importance of palmitoleic acid to adipocyte insulin resistance and whole-body insulin sensitivity in type 1 diabetes. J Clin Endocrinol Metab. 2013; 98: E40-E50.
31. Donga E, van Dijk M, Hoogma RP, Corssmit EP, Romijn JA. Insulin resistancein multiple tissuesin patients with type 1diabetes mellitus on long-term continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev. 2013; 29: 33-38.
32. Kacerovsky M, Brehm A, Chmelik M, et al. Impaired insulin stimulation of muscular ATP production in patients with type 1 diabetes. J Intern Med. 2011; 269: 189-199.
33. Hjøllund E, Pedersen O, Richelsen B, Beck-Nielsen H, Sørensen NS. Glucose transport and metabolism in adipocytes from newly diagnosed untreated insulin-dependent diabetics. Severely impaired basal and postinsulin binding activities. J Clin Invest. 1985; 76: 2091-2096.
34. Caruso M, Divertie GD, Jensen MD, Miles JM. Lack of effect of hyperglycemia on lipolysis in humans. Am J Physiol. 1990; 259: E542-E547.
35. Gerich JE Physiology of glucagon. Int Rev Physiol. 1981; 24: 243-275.
36. Jensen MD, Heiling VJ, Miles JM. Effects of glucagon on free fatty acid metabolism in humans. J Clin Endocrinol Metab. 1991; 72: 308-315.
37. Popp DA, Shah SD, Cryer PE. Role of epinephrine-mediated beta-adrenergic mechanisms in hypoglycemic glucose counterregulation and posthypoglycemic hyperglycemia in insulin-dependent diabetes mellitus. J Clin Invest. 1982; 69: 315-326.
38. Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014; XXX.
39. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappa B. Nat Med. 2005; 11: 183-190.
40. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012; 18: 363-374.
41. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006; 49: 442-451.
42. Pehling G, Tessari P, Gerich JE, Haymond MW, Service FJ, Rizza RA. Abnormal meal carbohydrate disposition in insulin-dependent diabetes. Relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy. J Clin Invest. 1984; 74: 985-991.
43. Mitrakou A, Kelley D, Veneman T, et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes. 1990; 39: 1381-1390.
44. Yki-Jarvinen H, Makimattila S. Insulin resistance due to hyperglycaemia: an adaptation protecting insulin-sensitive tissues. Diabetologia. 1997; 40(Suppl. 2): S141-S144.